DeCode's Q4 Revenues Rise 17 Percent as Loss Grows on Increased R&D Costs | GenomeWeb
NEW YORK (GenomeWeb News) — DeCode Genetics today said fourth-quarter revenues increased 17 percent as R&D spending rose 4 percent and lossed increased 10 percent.
 
Total receipts for the three months ended Dec. 31, 2006, rose to $11.5 million from $9.8 million year over year. DeCode said it has $9.8 million in deferred revenue which will be “recognized over future reporting periods.”
 
R&D spending increased to $14.2 million from $13.7 million year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.